PHMMF Company Profile and Key Details

Q: Who are the executives of PHMMF?

Mr. Jose Maria Fernandez Sousa-FaroFounder, Executive Chairman, Chief Executive Officer & PresMr. Pedro Francisco Fernandez PuentesExecutive Vice-ChairmanMs. María Luisa de Francia CaballeroChief Financial OfficerMr. Juan Gomez PulidoGen. Counsel & Sec. of the Board of DirectorsMs. Sandra Llamera SanchezGlobal Compliance HeadMr. Juan NoguesDirector of International Marketing & SalesMs. Belén Sopesén Veramendi Ph.D.Director of Corporation Devel.Ms. Lara VadilloCommunication DirectorMs. Elena Calleja CrespoDirector of Fin. & Admin.Mr. José Luis Moreno Martinez-LosaDirector of Capital Markets & Investor Relations

PNK : PHMMF

Pharma Mar SA

$31.15

4.3+16.01%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pharma Mar, S.A. (PHMMF) stock remained unchanged at $94.60 a share on OTC. The stock opened at $94.60, fluctuating between $94.60 to $94.60 during the session.

Stock Snapshot

94.6

Prev. Close

1.64B

Market Cap

94.6

Day Low

24.88

P/E Ratio

3.80293

EPS (TTM)

-1.67

Cash Flow per Share

94.6

Open

17.32M

Number of Shares

94.6

Day High

80.39%

Free Float in %

10.97

Book Value

100

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 31, 2026	94.60	94.60	94.60	94.60	100
Aug 27, 2026	97.36	97.36	97.36	97.36	166
Aug 05, 2026	87.58	87.58	87.58	87.58	300
Jul 10, 2026	90.90	90.90	90.90	90.90	102
Jul 08, 2026	94.34	94.34	94.34	94.34	183
Jun 12, 2026	79.00	79.49	77.41	79.49	300
Apr 13, 2026	106.15	106.48	106.15	106.48	10.35K
Apr 06, 2026	100.60	100.60	100.60	100.60	5.5K
Mar 31, 2026	96.00	96.00	96.00	96.00	5.5K
Mar 11, 2026	92.19	92.19	92.19	92.19	3.75K
Feb 09, 2026	88.72	88.72	88.72	88.72	231
Feb 04, 2026	90.56	90.56	90.56	90.56	175
Jan 09, 2026	90.21	90.21	90.21	90.21	174
Dec 10, 2025	86.26	86.26	86.26	86.26	216
Nov 17, 2025	84.94	86.36	84.94	86.36	1.04K
Nov 13, 2025	85.34	85.34	85.34	85.34	100
Nov 12, 2025	86.34	86.34	86.34	86.34	100
Oct 14, 2025	93.75	93.75	93.00	93.00	277
Oct 07, 2025	102.75	102.75	102.75	102.75	100
Oct 06, 2025	104.38	104.38	104.38	104.38	100

Contact Details

Madrid, MA 28770

Spain

https://www.pharmamar.com 349 184 66000

About Company

Pharma Mar, S.A. is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of bioactive compounds derived from marine organisms, primarily targeting oncology applications. Its products and research initiatives reach across key markets including Spain, Italy, Germany, Ireland, the broader European Union, the United States, and other international territories. The company's operations are structured across three distinct segments: Oncology, Diagnostics, and RNA Interference. Within its oncology portfolio, Pharma Mar markets Yondelis®, prescribed for soft tissue sarcomas and ovarian cancer, alongside Aplidin® for multiple myeloma, and Zepzelca®, which addresses small cell lung cancer. Additionally, the company has PM14, currently undergoing Phase II clinical trials for the treatment of various solid tumors. Beyond oncology, the Diagnostics segment is involved in the development and sale of diagnostic kits. Furthermore, through its RNA Interference division, Pharma Mar is advancing therapeutics designed to modulate or silence gene expression for therapeutic benefit. Established in 1986, the company maintains its headquarters in Madrid, Spain.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $77.41 and $110.40. With a market capitalization of about $1.64 billion, Pharma Mar, S.A. is classified as a small-cap and shows lower-than-market volatility (beta ~0.67). Key stats such as the average daily volume over the past year has been around 17.00 shares, trading with heavier-than-usual volume. Headquartered in Madrid, MA, Pharma Mar, S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jose Maria Fernandez Sousa-Faro, the company employs approximately 505 people and listed since February 23, 2016. Pharma Mar, S.A.

Valuation Metrics

Pharma Mar, S.A. trades at a P/E ratio of 25.31, slightly below the S&P 500 average, with a price-to-sales ratio of 6.52 and a price-to-book ratio of 5.69 trading at moderately above to book value. The P/FCF stands at 27.91, also above market averages.

Dividend & Fair Value

Pharma Mar, S.A. last paid a dividend of 1.14 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.89. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Pharma Mar, S.A. earnings surprise history is a mixed track record. The quarter that ended July 29, 2026, missed forecasts by -128.17%. The prior quarter beat by 1083.39%. Over the last six quarters, Apple has recorded several small beats. These include -173.41% in April 21, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Pharma Mar SA generated $158.15M in revenue, or $8.83 per share. Gross margin was 91.60%, operating margin -3.38%, and net profit margin 0.72%. Returns are modest, with ROA at 0.33% and ROE at 0.59%.
On valuation metrics, Pharma Mar SA trades at a P/E of 25.31, P/S of 6.52 and P/B of 5.69. The current ratio is 2.85 and quick ratio is 2.35. Operationally, the company’s inventory turnover is 0.37 and cash conversion cycle is 289.01 days. Debt-to-equity is 0.18, supported by a cash flow-to-debt ratio of 1.36.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pharma Mar SA posted revenue of $158.15M, down slightly from $196.34M in the prior quarter. Gross profit was $144.86M (margin 91.60%). Operating income was - $5.35M (margin -3.4%). Net income was$1.14M (EPS $0.06).
The company ended the quarter with $162.56M in cash and short-term investments, a total debt of $43.37M, and net debt of - $16.66M. Total assets were $341.22M, with equity of $193.44M. Financials further reflected weakness, with operating cash flow of - $13.45M, free cash flow of - $29.40M, and capital expenditures of - $15.96M.

Price Forecast & Outlook

Our AI price prediction model suggests that Pharma Mar, S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Pharma Mar, S.A. trading at a premium to the broader market with a P/E of 25.31.

Frequently Asked Questions

What is the current Pharma Mar, S.A. (PHMMF) stock price?

Pharma Mar, S.A. (OTC: PHMMF) stock price is $94.60 in the last trading session. During the trading session, PHMMF stock reached the peak price of $94.60 while $94.60 was the lowest point it dropped to. The percentage change in PHMMF stock occurred in the recent session was 0% while the dollar amount for the price change in PHMMF stock was $0.00.

PHMMF's industry and sector of operation?

The OTC listed PHMMF is part of Biotechnology industry that operates in the broader Healthcare sector. Pharma Mar, S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PHMMF?

Mr. Jose Maria Fernandez Sousa-Faro
Founder, Executive Chairman, Chief Executive Officer & Pres
Mr. Pedro Francisco Fernandez Puentes
Executive Vice-Chairman
Ms. María Luisa de Francia Caballero
Chief Financial Officer
Mr. Juan Gomez Pulido
Gen. Counsel & Sec. of the Board of Directors
Ms. Sandra Llamera Sanchez
Global Compliance Head
Mr. Juan Nogues
Director of International Marketing & Sales
Ms. Belén Sopesén Veramendi Ph.D.
Director of Corporation Devel.
Ms. Lara Vadillo
Communication Director
Ms. Elena Calleja Crespo
Director of Fin. & Admin.
Mr. José Luis Moreno Martinez-Losa
Director of Capital Markets & Investor Relations

How PHMMF did perform over past 52-week?

PHMMF's closing price is 16.02% higher than its 52-week low of $77.41 where as its distance from 52-week high of $110.40 is -32.66%.

How many employees does PHMMF have?

Number of PHMMF employees currently stands at 505.

Link for PHMMF official website?

Official Website of PHMMF is: https://www.pharmamar.com

How do I contact PHMMF?

PHMMF could be contacted at phone 349 184 66000 and can also be accessed through its website. PHMMF operates from Avenida de los Reyes, 1, Madrid, MA 28770, Spain.

How many shares of PHMMF are traded daily?

PHMMF stock volume for the day was 100 shares. The average number of PHMMF shares traded daily for last 3 months was 17.

What is the market cap of PHMMF currently?

The market value of PHMMF currently stands at $1.64B with its latest stock price at $94.60 and 17.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	505
Beta	0.67
Sales or Revenue	$158.15M
5Y Sales Change%	0.003%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PHMMF Company Profile and Key Details

Pharma Mar SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics